Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
about
Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancerAdeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude miceOncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAILTreatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy.Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemiaReprogrammed viruses as cancer therapeutics: targeted, armed and shielded.TRAIL gene therapy: from preclinical development to clinical application.TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.Oncolytic-adenovirus-expressed RNA interference for cancer therapy.Oncolytic Immunotherapy for Treatment of Cancer.Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.A potential therapeutic strategy for malignant mesothelioma with gene medicine.Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus.Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.
P2860
Q33702030-27F384F6-FE10-4CA5-9A2A-F4AD584118FDQ34244279-31785646-99D5-4A15-B148-21FF60CF8FFCQ35783456-A19396EC-1251-4942-854E-D1A8D64DD846Q36209190-F73D4E2A-6F1D-4A44-838A-3283850089B9Q36663418-A2942C8D-B30C-4B89-8B13-A28DDAB90262Q36663422-5AF3CBE7-423F-49B7-9B5E-101317A268C7Q37132233-8F8E940A-DECA-4CF5-896A-9F25EC67340AQ37191007-310C2A3B-4D94-49F5-9CDC-AAB98C2EBCAFQ37307340-23A769E9-6E1A-400B-BEA3-725215670734Q37440765-340932AB-ACB0-40BE-9F57-A507682BD310Q37586895-DED302D5-4E5B-454A-9A63-7AA44B317A4FQ37777745-4B76ACA9-B4B7-4238-8B6E-01DD44075196Q38848223-3D4D1DFC-31D7-4E4F-A37B-D7A260831A3DQ38918317-5FBEC814-4B88-40AE-BAE0-00ED69C4D3E9Q39792478-7EDE1DB5-15CF-4FFB-96A5-92DD5D730124Q41846143-6C92559E-3075-409E-B1B1-BD31D745B2D9Q45865848-58ED8EF2-42F0-4896-83C0-FB3E06ED3C69Q52731749-0CEA7D0F-4286-4D2A-9FC8-C7A205C1EA69
P2860
Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Eliminating established tumor ...... nd-armed oncolytic adenovirus.
@ast
Eliminating established tumor ...... nd-armed oncolytic adenovirus.
@en
type
label
Eliminating established tumor ...... nd-armed oncolytic adenovirus.
@ast
Eliminating established tumor ...... nd-armed oncolytic adenovirus.
@en
prefLabel
Eliminating established tumor ...... nd-armed oncolytic adenovirus.
@ast
Eliminating established tumor ...... nd-armed oncolytic adenovirus.
@en
P2093
P2860
P1476
Eliminating established tumor ...... nd-armed oncolytic adenovirus.
@en
P2093
Bingliang Fang
Fengqin Dong
Fuminori Teraishi
John J Davis
Lidong Zhang
Wenxian Hu
P2860
P304
P356
10.1158/1078-0432.CCR-06-0244
P407
P577
2006-09-01T00:00:00Z